VP of Research
Spirovant Sciences, Inc
Kate Excoffon is currently VP of Research at Spirovant Sciences, Inc., a biotech company focused on curing CF, in Philadelphia PA. With over 25 years of experience in gene therapy in the academic and biotech space, Kate’s passion is creating, building, and advancing viral vector-mediated gene therapy, with a carreer-long focus on curing CF. Early academic discoveries led to the creation of Glybera, the first gene therapy approved in the Western world. Later work led to the discovery of novel AAV vectors with high tropism for the human airway and CD4+ T cells. With over 50 publications, hundreds of presentations, numerous grants, patents, and trainees, she is a recognized expert in AAV, adenovirus, and lentivirus-based vectors and basic molecular virology. Kate’s training was at University of British Columbia (PhD) and University of Iowa. Prior to Spirovant Sciences, Inc., Kate was a full professor at Wright State University in Dayton OH.